CDXC Stock Overview
Operates as a bioscience company focusing on developing healthy aging products. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ChromaDex Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.50 |
| 52 Week High | US$7.67 |
| 52 Week Low | US$1.32 |
| Beta | 1.88 |
| 11 Month Change | 116.76% |
| 3 Month Change | 127.96% |
| 1 Year Change | 417.24% |
| 33 Year Change | 50.00% |
| 5 Year Change | 96.34% |
| Change since IPO | -33.33% |
Recent News & Updates
ChromaDex's (NASDAQ:CDXC) Solid Earnings Are Supported By Other Strong Factors
Nov 07
Revenues Tell The Story For ChromaDex Corporation (NASDAQ:CDXC) As Its Stock Soars 70%
Nov 05Recent updates
ChromaDex's (NASDAQ:CDXC) Solid Earnings Are Supported By Other Strong Factors
Nov 07Revenues Tell The Story For ChromaDex Corporation (NASDAQ:CDXC) As Its Stock Soars 70%
Nov 05ChromaDex Corporation (NASDAQ:CDXC) Stock Rockets 25% But Many Are Still Ignoring The Company
Jul 25Shareholders Will Likely Find ChromaDex Corporation's (NASDAQ:CDXC) CEO Compensation Acceptable
Jun 15Positive Sentiment Still Eludes ChromaDex Corporation (NASDAQ:CDXC) Following 26% Share Price Slump
Jun 05Should You Think About Buying ChromaDex Corporation (NASDAQ:CDXC) Now?
Apr 05Not Many Are Piling Into ChromaDex Corporation (NASDAQ:CDXC) Just Yet
Feb 28ChromaDex Corporation's (NASDAQ:CDXC) Intrinsic Value Is Potentially 85% Above Its Share Price
Jan 29Market Cool On ChromaDex Corporation's (NASDAQ:CDXC) Revenues
Jun 08We're Hopeful That ChromaDex (NASDAQ:CDXC) Will Use Its Cash Wisely
Mar 31ChromaDex inks new commercial supply agreement for its Niagen ingredient with Nestlé
Oct 11ChromaDex forms JV in Asia for Tru Niagen; plans to raise $3.1M via stock sale
Oct 03ChromaDex in pact to introduce anti-aging compound in Brazil
Sep 01Ayana Bio appoints Frank Jaksch as CEO
Aug 24ChromaDex wins patent challenge as US regulator rejects Thorne Research's demand to invalidate patent
Aug 15Shareholder Returns
| CDXC | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 7.0% | -5.8% | -1.0% |
| 1Y | 417.2% | 1.7% | 30.3% |
Return vs Industry: CDXC exceeded the US Life Sciences industry which returned 1.2% over the past year.
Return vs Market: CDXC exceeded the US Market which returned 30.4% over the past year.
Price Volatility
| CDXC volatility | |
|---|---|
| CDXC Average Weekly Movement | 20.4% |
| Life Sciences Industry Average Movement | 8.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CDXC's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CDXC's weekly volatility has increased from 15% to 20% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 106 | Rob Fried | www.chromadex.com |
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
ChromaDex Corporation Fundamentals Summary
| CDXC fundamental statistics | |
|---|---|
| Market cap | US$575.66m |
| Earnings (TTM) | US$1.49m |
| Revenue (TTM) | US$91.67m |
386.6x
P/E Ratio6.3x
P/S RatioIs CDXC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CDXC income statement (TTM) | |
|---|---|
| Revenue | US$91.67m |
| Cost of Revenue | US$35.34m |
| Gross Profit | US$56.33m |
| Other Expenses | US$54.84m |
| Earnings | US$1.49m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.019 |
| Gross Margin | 61.45% |
| Net Profit Margin | 1.62% |
| Debt/Equity Ratio | 0% |
How did CDXC perform over the long term?
See historical performance and comparison